Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SB-772077B is a Rho-associated kinase (ROCK) inhibitor (IC50s = 5.6 and 6 nM for ROCK1 and ROCK2, respectively).1 It is selective for ROCK1 and ROCK2 over Akt1, Akt2, and Akt3 (IC50s = 324, 1,950, and 1,290 nM, respectively), as well as Cdk2, GSK3α, IKKβ, JNK3, and Plk (IC50s = ≥7,000 nM for all), but also inhibits RSK1 and MSK1 (IC50s = 35 and 14 nM, respectively). SB-772077B inhibits LPS-induced TNF-α and IL-6 production in THP-1 cells in a concentration-dependent manner. It induces relaxation of pre-contracted isolated rat aortic rings (IC50 = 39 nM). It reduces blood pressure in spontaneously hypertensive rats in a dose-dependent manner and in DOCA-salt hypertensive rats when administered at a dose of 1 mg/kg. SB-772077B (30, 100, and 300 μg/kg, i.v.) reduces pulmonary and systemic arterial pressure and increases cardiac output in normotensive rats and rats with monocrotaline-induced pulmonary hypertension.2
WARNING This product is not for human or veterinary use.
1. Novel Rho kinase inhibitors with anti-
2. Analysis of pulmonary vasodilator responses to SB-